Implications for Management of PET Amyloid Classification Technology

Brief Summary

Detailed Description

The primary purpose of this prospective, observational study is to examine the benefit of \[18F\]Flutemetamol PET/CT scan in clinical practice for early diagnosis of cognitive impairment and identifying Alzheimer's disease (AD) pathology. To accomplish this, when a clinician has ordered an amyloid positron emission tomography (PET) scan, the investigators will assess the impact of \[18F\]Flutemetamol PET/CT scans on 1) physician diagnosis and management as it relates to care practices and drug management, and 2) patient reported outcomes in patients evaluated in the Cognitive Disorders Clinic at the University of Utah and meeting Appropriate Use Criteria (AUC) for clinical amyloid PET/CT scans. A secondary purpose is to compare the semi-quantitative assessment of amyloid plaque burden using vendor supplied software and standard visual assessment of amyloid positivity. The primary hypothesis is that, in diagnostically uncertain cases, knowledge of amyloid status as determined by amyloid PET/CT scans may alter patient diagnosis and management and lead to significant changes in patient and family reported outcomes. A secondary hypothesis is that vendor supplied semi-quantitative assessment of amyloid plaque positivity will be superior to standard visual criteria assessments. Aims: Aim 1: To assess the change in diagnosis and management including both care practices and drug management of adult patients being evaluated for cognitive deficits and meeting Appropriate Use Criteria (AUC). Aim 2: To assess the change of amyloid PET/CT scans on patient-reported outcomes involving care partner confidence and satisfaction. Aim 3: To assess the confidence of visual interpretation by using vendor supplied semi-quantitative software to assess amyloid plaque burden. Hypotheses to be Tested - Synopsis The hypothesis is that to aid early diagnosis, individuals with a diagnostically uncertain etiology for their dementia will benefit from knowledge of amyloid plaque burden status through an alteration of patient diagnosis and management, which will lead to significant changes in patient and care partner reported outcomes. Aim 1 1. Amyloid PET will change physician judgment of the likelihood of AD 2. Amyloid PET will change the leading diagnosis in more than 25% of cases 3. Amyloid PET will increase physician diagnostic confidence in the leading diagnosis 4. Amyloid PET will change more than 25% of care practice options from pre-scan management 5. Amyloid PET will change more than 25% of drug management options Aim 2 1. Care partners are more confident in the diagnosis after the scan than before the scan 2. Care partners will be more satisfied with multidisciplinary cognitive specialty team evaluation than previous evaluation 3. Care partners will be more satisfied with multidisciplinary cognitive specialty team evaluation with amyloid PET than than the evaluation non-specialists performed without amyloid PET 4. Care partners will find amyloid PET not very burdensome if the doctor finds a scan helpful 5. Based upon their experience with the amyloid PET scan, a majority of the care partners would still agree to have an amyloid PET scan performed if it were requested by the specialist 6. Care partners will find that amyloid PET did not cause an increase in adverse reactions (scan visit) than standard routine clinic visit (post-scan visit) 7. Care partners will find that the diagnostic clinic visit (post-scan visit) did not cause an increase in adverse reactions than the first clinic visit (pre-scan visit) Aim 3: 1. Confidence of radiologist / nuclear medicine physician interpretation of scans increases after adding quantitative analysis as compared to qualitative analysis alone This study will use \[18F\]Flutemetamol-PET imaging to assess and quantify the amyloid plaque burden in patients with mild cognitive impairment (MCI) or dementia of unclear etiology, according to Diagnostic Statistical Manual-IV (DSM-IV) and/or National Institutes of Aging-Alzheimer's Association criteria, verified by a dementia specialist within 24 months. The \[18F\]Flutemetamol-PET scans of these study participants will then be assessed using a General Electric (GE) software databases (NeuroMarQ) which contain scan data from healthy control individuals to evaluate for abnormalities in amyloid plaque burden differing from the values expected for individuals in their age range.

Primary Outcomes

Secondary Outcomes

• Change in care partner assessment of the quality of evaluation after amyloid PET(Visit 1, 30 days prior to scan and Visit 4, 90 days after scan)
• Percentage of recommended care practices adhered to after amyloid PET scan(Visit 4 90 days post scan)
• Change in % likelihood of Alzheimer's disease (AD) diagnosis after amyloid PET scan(Visit 1, 30 days prior to scan and Visit 4, 90 days after scan)
• Proportion of change in leading diagnosis after amyloid PET(Visit 1, 30 days prior to scan and Visit 4, 90 days after scan)
• Proportion exhibiting increased behavior disturbance during amyloid scan visit(at each visit, visits1-4, 120 days)
• Change in physician confidence in leading diagnosis(Visit 1, 30 days prior to scan and Visit 4, 90 days after scan)
• Proportion exhibiting increased behavior disturbance when the diagnosis is given(Visit 1, Visit 3, 60 days)
• Percentage of recommended drug management adhered to after amyloid PET scan(Visit 4 90 days post scan)
• Proportion of care partners finding amyloid PET scan worthwhile(Visit 4, 90 days after scan)
• Proportion of drug management options changed after amyloid PET(Visit 1, 30 days prior to scan and Visit 4, 90 days after scan)
• Change in care partner's confidence in diagnosis after amyloid PET(Visit 1, 30 days prior to scan and Visit 4, 90 days after scan)
• Change in care partner satisfaction with evaluation after amyloid PET(Visit 1, 30 days prior to scan and Visit 4, 90 days after scan)